Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Fenpiverinium→

Fenpiverinium Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
258329-46-3
Molecular formula
C22H29N2O+
Molecular weight
337.5 g/mol
Drug class
Quaternary ammonium antimuscarinicantispasmodic component of fixed-dose analgesic combinations
Mechanism of action
Antagonises muscarinic acetylcholine receptors in visceral smooth muscle, reducing cholinergic tone and intestinal, biliary and urinary tract spasm. It is commonly used in combination with metamizole and pitofenone rather than as a stand-alone product.
Indications / reported uses
  • Component of fixed-dose combinations used for short-term symptomatic relief of painful gastrointestinal, biliary or urinary smooth-muscle spasm, where authorised.

Sources: https://pubmed.ncbi.nlm.nih.gov/6719639/ · https://www.rlsnet.ru/active-substance/metamizol-natriya-pitofenon-fenpiveriniya-bromid-246 · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Fenpiverinium Environmental Risk Assessment (ERA) (the Fenpiverinium ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.